Under Armour Inc Class A vs Zoetis Inc — how do they compare? Under Armour Inc Class A trades at $5.09 (market cap $2.26B), while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 13.8× Under Armour Inc Class A's market cap, and Zoetis Inc pays a 2.81% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| UA | ZTS | |
|---|---|---|
Market Cap | $2.26B | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.88 | $156.76 |
52-Week Low | $3.96 | $71.91 |
Enterprise Value | $3.24B | $38.70B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Under Armour (UA) is trading at $5.12, down 9.78% with bearish technical signals despite some oversold RSI readings. The company faces significant fundamental challenges with negative net income margins (-9.99%) and declining revenue trends from $5.16B in 2025 to $4.9B in 2026. Recent Q1 2027 results showed a revenue decline of 3% to $1.1B, prompting management to lower full-year revenue guidance amid softer consumer demand in key markets.
The outlook remains challenging with persistent profitability issues and negative cash flow trends. While analyst sentiment shows mixed ratings (38.81% Buy, 49.25% Hold), the stock trades at attractive valuation multiples (P/S 0.45) but faces execution risks in its turnaround strategy. Key risks include competitive pressures, inventory management challenges, and macroeconomic headwinds affecting consumer spending.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →